Please assess the completion status of the following clinical trial:

Trial Title: Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Age \>18~* Able to provide written informed consent and willing to participate in all required study follow-up assessments~* Symptomatic CAD with refractory angina defined as CCS class II to IV, despite optimal tolerated medical therapy~* Abnormal coronary microvascular function indices: CFR≤2.5 and/or IMR≥25~Exclusion Criteria~* Recent (within 3 months) acute coronary syndrome~* Patients with prior coronary artery bypass surgery~* Unstable angina (recent onset angina, crescendo angina, or rest angina with ECG changes) during the last 30 days~* Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors or intraaortic counter pulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.~* Obstructive CAD on coronary angiography (\>70% stenosis or 50-70% stenosis with iFR\<0.89 or FFR\<0.8 in epicardial artery)~* Inability to perform invasive coronary flow evaluation and/or measure CFR and IMR in the LAD~* Severe valvular heart disease~* LVEF\<30%~* Decompensated congestive heart failure (CHF) or hospitalization due to CHF during the last 3 months~* Patient with a pacemaker electrode in the CS~* Mean right atrial pressure \>15 mmHg~* Anomalous or abnormal CS anatomy (e.g., tortuosity, aberrant branch, persistent left superior vena cava (SVC) as demonstrated on angiogram~* CS diameter at the site of planned implantation greater than 13mm or less than 9.5 mm as measured by angiogram~* Severe chronic obstructive pulmonary disease (COPD) indicated by a forced expiratory volume in one second that is less than 55 percent of the predicted value~* Tricuspid valve replacement or repair (tissue or mechanical)~* Chronic renal failure (serum creatinine \>2mg/dL), and or on chronic hemodialysis~* Moribund, or with comorbidities limiting life expectancy to less than one year~* Known severe reaction to required procedural medication~* Known allergy to stainless steel or nickel~* Magnetic Resonance Imaging (MRI) within 8 weeks of Reducer implantation~* Participation in another ongoing investigational trial~* Additional factors deemed unsuitable for trial enrollment per discretion of principal investigator~* Inmates

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Refractory Angina (Type: EXPERIMENTAL): Subjects with chronic refractory angina will undergo implantation of the Neovasc Reducer™ System in the cardiac catheterization laboratory.

Based on this trial design, predict the completion outcome and termination type (if applicable).